EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseOpen Access · CC BY 4.0

Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis

Young Ho Lee, Gwan Gyu Song

Pharmacology · 2023

DOI: 10.1159/000527186 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Pharmacology, 2023. Verfasst von Young Ho Lee und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Antirheumatic Agents, Janus Kinase Inhibitors, Arthritis, Rheumatoid. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The relative efficacy of Janus kinase (JAK) inhibitors in producing remission and low disease activity (LDA) states remains unknown since there are currently no trials that provide direct comparisons among JAK inhibitors in disease-modifying antirheumatic drug (DMARD)-naive patients with rheumatoid arthritis (RA).

Objectives

This study aimed to assess the relative remission and LDA rates of tofacitinib, baricitinib, upadacitinib, and filgotinib compared to those of methotrexate (MTX) in DMARD-naive patients with RA.

Method

We conducted Bayesian network meta-analysis and included information from direct and indirect comparisons from randomized controlled trials that examined remission (Disease Activity Score in 28 Joints using C-reactive protein level [DAS28-CRP]

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsJanus Kinase InhibitorsArthritis, RheumatoidHumansMethotrexateBayes TheoremTreatment OutcomeDrug Therapy, CombinationPiperidinesPyrimidinesPyridinesTriazolesAzetidinesPurinesPyrazolesSulfonamidesHeterocyclic Compounds, 3-Ring

Stichwörter der Autor:innen

Janus kinase inhibitorsLow disease activityNetwork meta-analysisRemissionRheumatoid arthritis

Substanzen

MethotrexateAntirheumatic AgentsJanus Kinase InhibitorstofacitinibPiperidinesPyrimidinesGLPG0634PyridinesTriazolesbaricitinib

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.

Zitieren

APA

Lee, Y. H., & Song, G. G. (2023). Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis. Pharmacology. https://doi.org/10.1159/000527186

Vancouver

Lee YH, Song GG. Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis. Pharmacology. 2023. doi:10.1159/000527186

BibTeX
@article{Lee2023,
  author = {Lee, Young Ho and Song, Gwan Gyu},
  title = {Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis},
  journal = {Pharmacology},
  year = {2023},
  doi = {10.1159/000527186}
}
Kostenlos starten →